Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ADHD Black Box Warning On Psychiatric/Cardiac Events Is Unnecessary, Pediatric Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Pediatric Advisory Committee recommends adding regular warnings on possible psychosis, aggression, and cardiovascular risks to all attention deficit/hyperactivity disorder drugs.

You may also be interested in...



GSK Dexedrine Adds Black Box On Cardiovascular Events

ADHD product also adds class warnings on psychiatric events, seizures and visual disturbance.

GSK Dexedrine Adds Black Box On Cardiovascular Events

ADHD product also adds class warnings on psychiatric events, seizures and visual disturbance.

ADHD Drug Prescription Trends Are Determined By Side Effect Profile, Study Finds

Study in Journal of Managed Care Pharmacy finds more patients are prescribed atomoxetine when they have psychiatric conditions that could be exaggerated by stimulants.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel